Epicardial Injections of Allogenic Human Induced Pluripotent Stem Cells-derived Cardiomyocytes for Severe Chronic Ischemic Heart Failure: The HEAL-CHF Trial

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Heart failure continues to impose a significant global health burden, with a continuous search for therapies capable of promoting a true myocardial regeneration. The HEAL-CHF trial evaluated the safety and efficacy of intramyocardial injections of allogeneic human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in advanced heart failure (LVEF≤45%) patients with concomittent coronary artery bypass grafting (CABG). The primary safety endpoints, defined as the incidence of sustained ventricular arrhythmias at 1-6-month follow-up and tumorigenicity at 12-month follow-up, were not observed. Efficacy analyses suggested benefits of cell transplantation compared with CABG alone, primarily evidenced by significant improvements in 6-minute walk distance (6MWD), stroke volume (SV), myocardial perfusion recovery and myocardial contractility. This first randomized and controlled clinical trial of human iPSC-based cardiac regenerative therapy demonstrates the safety and therapeutic potential of hiPSC-CMs and provides a strong incentive for moving to trials adequately powered to yield robust efficacy data. (ClinicalTrials.gov registration: NCT03763136.)

Article activity feed